The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2024
Filed:
Jan. 20, 2023
Applicant:
Zymeworks Bc Inc., Vancouver, CA;
Inventors:
Geoffrey C. Winters, Vancouver, CA;
James R. Rich, Vancouver, CA;
Graham Albert Edwin Garnett, West Vancouver, CA;
Alexander Laurence Mandel, Vancouver, CA;
Tom Han Hsiao Hsieh, Vancouver, CA;
Elyse Marie Josée Bourque, L'Etang-du-Nord, CA;
Stuart Daniel Barnscher, Langley, CA;
Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07D 207/08 (2006.01); C07D 207/448 (2006.01); C07K 5/02 (2006.01); C07K 7/02 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); H01L 25/16 (2023.01); H10K 59/131 (2023.01); H10K 59/18 (2023.01); H10K 71/00 (2023.01); H10K 77/10 (2023.01); H10K 59/12 (2023.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 38/06 (2013.01); A61K 47/54 (2017.08); A61K 47/6813 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6867 (2017.08); C07K 5/0205 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); H01L 25/162 (2013.01); H01L 25/167 (2013.01); H10K 59/131 (2023.02); H10K 59/18 (2023.02); H10K 71/00 (2023.02); H10K 77/111 (2023.02); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); H10K 59/1201 (2023.02);
Abstract
Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.